A pan-European survey across 24 sleep centres in 14 countries reveals that tirzepatide and other GLP-1 receptor agonists are rapidly entering sleep medicine practice, yet clinical protocols remain deeply fragmented. Only 42% of centres allow sleep physicians to initiate GLP-1RA therapy directly. While 92% continue recommending diagnostic sleep studies for symptomatic patients already on these drugs, a striking 86% of centres fail to proactively re-titrate or withdraw positive airway pressure (PAP) therapy despite anticipating meaningful OSA severity reductions. A >10% body weight loss threshold for OSA reassessment was endorsed by 61% of centres.
The disconnect exposed here is clinically significant. Tirzepatide's SURMOUNT-OSA trial demonstrated approximately 25–30% reductions in apnea-hypopnea index alongside substantial weight loss — effects large enough to potentially eliminate therapeutic PAP requirements in a meaningful patient subset. Yet most European sleep centres are operating reactively rather than building proactive interdisciplinary reassessment pathways. This creates real patient risk: continued, unnecessary PAP dependence on one end, or inadequately monitored OSA on the other.
As a survey study, the findings reflect reported intentions rather than verified clinical behavior, and 24 centres across 14 countries cannot fully represent European practice diversity. Still, this is one of the first systematic snapshots of GLP-1RA integration into sleep medicine, and its signal is clear: regulatory approval has outpaced clinical infrastructure. For longevity-conscious adults managing obesity-related OSA, the practical takeaway is that treatment optimization now requires actively advocating for follow-up sleep studies after sustained weight loss.